Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Snap Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Snap Inc trades at $5.5 (market cap $9.32B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.2× Snap Inc's market cap, and Snap Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SNAP | |
|---|---|---|
Market Cap | $29.60B | $9.32B |
Sector | Health | Media |
52-Week High | $491.22 | $9.09 |
52-Week Low | $205.48 | $3.93 |
Enterprise Value | $27.56B | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Snap Inc. (SNAP) trades at $5.34, up 0.19% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with Q2 2026 revenue growth of 19% year-over-year to $1.60 billion and a narrowing net loss, beating analyst expectations. Operating cash flow strengthened to $656 million in 2025, while the stock trades below the consensus price target of $7.02 with 38% of analysts rating it a buy.
The outlook suggests potential upside from continued advertising revenue growth and cost discipline, but risks include persistent net losses, high debt levels, and competitive pressures in social media. Investor sentiment is cautiously optimistic amid earnings beats and insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
